ClinicalTrials.gg
CompletedNCT02833844Updated Jul 22, 2022Results posted

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

A Phase 3 interventional study of Evolocumab and Placebo in Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection, sponsored by Amgen. Completed at 78 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-22.

Primary conditionHyperlipidemiasRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hyperlipidemias
Why
  1. The study's listed conditions name Hyperlipidemias, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
467
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
7th of 21
467 · median 307
Started
2017
with 1 other
Phase 3
12 of 21
none open now
Registered
16th of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 16th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM) or placebo QM. The second part of the study is a 24-week open label extension period. During this time all participants will receive evolocumab QM.

The clinical hypothesis is that subcutaneous evolocumab QM will be well tolerated and will result in greater reduction of low density lipoprotein cholesterol (LDL-C), defined as percent change from baseline at Week 24, compared with placebo QM in human immunodeficiency virus (HIV)-positive participants with hyperlipidemia or mixed dyslipidemia.

03

Conditions studied

  • Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection

Browse trials for

Keywords

  • Hyperlipidemia
  • Dyslipidemia
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9)
  • Inhibition
  • HIV infection
  • Cluster of differentiation
  • Viral load
04

In context

Hyperlipidemias Reclassified

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

This study's enrollment of 467 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.

Browse Hyperlipidemias studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Hyperlipidemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 years of age
  • Known infection with stable HIV therapy for ≥ 6 months
  • Cluster of differentiation 4 (CD4) ≥ 250 cells/mm\^3 for ≥ 6 months
  • HIV viral load ≤ 50 copies/mL at screening and ≤ 200 copies/mL for ≥ 6 months
  • Subject on stable lipid-lowering therapy for ≥ 4 weeks prior to randomization and not expected to change during the duration of study
  • For subjects with known clinical atherosclerotic cardiovascular disease (ASCVD), fasting LDL-C of ≥ 70 mg/dL or non-high density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL. For subjects without known clinical ASCVD: fasting LDL-C of ≥ 100 mg/dL or non-HDL-C of ≥ 130 mg/dL
  • Fasting triglycerides ≤ 600 mg/dL (6.8 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • Taking a combination of background lipid-lowering therapy and therapy known to have significant drug-drug interaction
  • (NYHA) III or IV heart failure, or last known (LVEF) \< 30%
  • Known opportunistic infection/acquired immunodeficiency syndrome (AIDS) defining illness within 1 year prior to randomization
  • Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months
  • Type 1 diabetes, new-onset or poorly controlled type 2 diabetes
  • Uncontrolled hypertension
  • Taken a cholesteryl ester transfer protein inhibitor in the last 12 months
  • Moderate to severe renal dysfunction
  • Persistent active liver disease or hepatic dysfunction (Stable chronic of at least 1 year duration prior to randomization is allowed)
  • (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization

Other exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
467 participants (actual)

Study arms

  • Experimental
    Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM

    Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.

    Drug: Evolocumab · Drug: Placebo

  • Placebo comparator
    Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM

    Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.

    Drug: Evolocumab

Interventions

  • Dose of subcutaneous evolocumab QM

    Also known as: EvoMab, Repatha, AMG 145

  • DrugPlacebo

    Dose of matching placebo QM

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in LDL-C at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

  2. Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24

    Time frame: Week 24

  3. Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24

    Time frame: Baseline, Week 24

  4. Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

  5. Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

  6. Percent Change From Baseline in Total Cholesterol (TC) at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

  7. Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

  8. Percent Change From Baseline in Triglycerides at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

  9. Percent Change From Baseline in HDL-C at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Bseline, Week 24

  10. Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24

    Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

    Time frame: Baseline, Week 24

08

Results

Posted Jul 21, 2020

Participant flow

This study was conducted at 72 centers in Australia, Belgium, Brazil, Canada, France, Greece, Italy, Poland, Portugal, Romania, South Africa, Spain, Switzerland, United Kingdom, and United States. The first participant was enrolled on 22 May 2017, and the last participant was enrolled on 23 January 2019.

Double-Blind Period
Participant flow — Double-Blind Period
MilestoneDouble-Blind Placebo/Open-Label EvolocumabDouble-Blind Evolocumab/Open-Label Evolocumab
Started157310
Randomized and treated157307
Completed155303
Not completed27
Withdrew: Withdrawal by subject23
Withdrew: Protocol violation04
Open-Label Period
Participant flow — Open-Label Period
MilestoneDouble-Blind Placebo/Open-Label EvolocumabDouble-Blind Evolocumab/Open-Label Evolocumab
Started152303
Received open-label study drug152299
Completed150301
Not completed22
Withdrew: Death02
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercent Change From Baseline in LDL-C at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in LDL-C at Week 241.68 ± 2.03-55.23 ± 1.52
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -56.92 · 95% CI -61.55 to -52.28Treatment difference uses placebo as the reference.
SecondaryChange From Baseline in LDL-C at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 24
mg/dLDouble-Blind PlaceboDouble-Blind Evolocumab
Change From Baseline in LDL-C at Week 24-2.3 ± 3.1-77.5 ± 2.3
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -75.2 · 95% CI -82.1 to -68.4Treatment difference uses placebo as the reference.
SecondaryPercentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24
Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24
percentage of participantsDouble-Blind PlaceboDouble-Blind Evolocumab
Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 247.9 (4.6 to 13.4)73.3 (68.0 to 78.0)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · Cochran-Mantel-Haenszel · p = < 0.0001 (Based on Cochran-Mantel-Haenszel test stratified by statin use stratification factor. For testing, nonachievement was imputed for participants with a missing value.) · Treatment difference: 65.4 · 95% CI 57.8 to 71.1Treatment difference uses placebo as reference.
SecondaryPercentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24
Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24
percentage of participantsDouble-Blind PlaceboDouble-Blind Evolocumab
Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 240.7 (0.1 to 3.7)72.5 (67.2 to 77.3)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · Cochran-Mantel-Haenszel · p = < 0.0001 (Based on Cochran-Mantel-Haenszel test stratified by statin use stratification factor. For testing, nonachievement was imputed for participants with a missing value.) · Treatment difference: 71.9 · 95% CI 65.7 to 76.7Treatment difference uses placebo as a reference.
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 242.86 ± 1.74-48.07 ± 1.31
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -50.94 · 95% CI -54.88 to -46.99Treatment difference uses placebo as the reference.
SecondaryPercent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 242.59 ± 1.50-45.14 ± 1.13
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -47.73 · 95% CI -51.11 to -44.35Treatment difference uses placebo as the reference.
SecondaryPercent Change From Baseline in Total Cholesterol (TC) at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (TC) at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in Total Cholesterol (TC) at Week 242.34 ± 1.40-35.78 ± 1.06
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -38.12 · 95% CI -41.30 to -34.94Treatment difference uses placebo as the reference.
SecondaryPercent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 2410.35 ± 3.34-16.44 ± 2.57
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -26.78 · 95% CI -34.17 to -19.40Treatment difference uses placebo as the reference.
SecondaryPercent Change From Baseline in Triglycerides at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in Triglycerides at Week 2413.21 ± 3.80-9.25 ± 2.89
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -22.46 · 95% CI -31.03 to -13.88Treatment difference uses placebo as the reference.
SecondaryPercent Change From Baseline in HDL-C at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Bseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in HDL-C at Week 242.73 ± 1.5711.08 ± 1.20
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: 8.36 · 95% CI 4.83 to 11.89Treatment difference uses placebo as the reference.
SecondaryPercent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24
percent changeDouble-Blind PlaceboDouble-Blind Evolocumab
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 2412.34 ± 3.54-9.81 ± 2.65
Statistical analysis
  • Double-Blind Placebo vs Double-Blind Evolocumab · repeated measures linear effects model · p = < 0.0001 (Multiplicity adjustment was based on the combination of sequential testing, the fallback procedure, and the Hochberg procedure.) · Treatment difference: -22.15 · 95% CI -30.04 to -14.26Treatment difference uses placebo as the reference.

Adverse events

Collected over Double-blind Treatment (DBT) Period: From randomization (for all-cause mortality) or first dose of study drug (for adverse events) to up to week 24. Open-label Extension (OLE) Period: From the start of the OLE (week 24) to end of study (week 52) for all-cause mortality; and from first dose of study drug in the OLE up to 30 days after last dose, or end of study, whichever was earlier, for adverse events.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Placebo0/157 (0%)8/157 (5.1%)41/157 (26.1%)
Double-Blind Evolocumab0/310 (0%)10/307 (3.3%)78/307 (25.4%)
Double-Blind Placebo/Open-Label Evolocumab0/152 (0%)8/152 (5.3%)23/152 (15.1%)
Double-Blind Evolocumab/Open-Label Evolocumab2/303 (0.7%)14/299 (4.7%)50/299 (16.7%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventDouble-Blind PlaceboDouble-Blind EvolocumabDouble-Blind Placebo/Open-Label EvolocumabDouble-Blind Evolocumab/Open-Label Evolocumab
OsteoarthritisMusculoskeletal and connective tissue disorders2/1570/3070/1520/299
Atrial fibrillationCardiac disorders1/1570/3071/1520/299
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1571/3071/1520/299
Blood loss anaemiaBlood and lymphatic system disorders0/1570/3071/1520/299
Gastric ulcerGastrointestinal disorders0/1570/3071/1520/299
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1570/3071/1520/299
Helicobacter gastritisInfections and infestations0/1570/3071/1520/299
Brain contusionInjury, poisoning and procedural complications0/1570/3071/1520/299
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1570/3071/1520/299
Basosquamous carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1570/3071/1520/299
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDouble-Blind PlaceboDouble-Blind EvolocumabDouble-Blind Placebo/Open-Label EvolocumabDouble-Blind Evolocumab/Open-Label Evolocumab
DiarrhoeaGastrointestinal disorders7/15711/3071/1528/299
NasopharyngitisInfections and infestations2/15710/3076/1529/299
Influenza like illnessGeneral disorders4/15712/3072/1523/299
Back painMusculoskeletal and connective tissue disorders4/15712/3074/1522/299
MyalgiaMusculoskeletal and connective tissue disorders6/1576/3070/1523/299
Chest painGeneral disorders5/1572/3070/1521/299
HeadacheNervous system disorders5/1576/3073/1521/299
HypertensionVascular disorders5/1570/3073/1524/299
ArthralgiaMusculoskeletal and connective tissue disorders3/1579/3071/1525/299
SinusitisInfections and infestations1/1571/3071/1528/299

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-Blind PlaceboDouble-Blind EvolocumabTotal
Mean56.2 ± 8.056.5 ± 9.156.4 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind PlaceboDouble-Blind EvolocumabTotal
Female374582
Male120265385
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind PlaceboDouble-Blind EvolocumabTotal
Hispanic or Latino214162
Not Hispanic or Latino136269405
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind PlaceboDouble-Blind EvolocumabTotal
Asian336
Black or African American255479
White125246371
Multiple Races101
Other, Not Specified3710
Stratification Factor: Statin Use at Baseline
Stratification Factor: Statin Use at Baseline(Participants)Double-Blind PlaceboDouble-Blind EvolocumabTotal
Statin Use = Yes128256384
Statin Use = No295483
Stratification Factor: Hepatitis C Virus (HCV) Status at Baseline
Stratification Factor: Hepatitis C Virus (HCV) Status at Baseline(Participants)Double-Blind PlaceboDouble-Blind EvolocumabTotal
HCV = Yes71017
HCV= No150300450
Low-Density Lipoprotein Cholesterol (LDL-C)
Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL)Double-Blind PlaceboDouble-Blind EvolocumabTotal
Mean133.26 ± 39.97133.25 ± 40.25133.25 ± 40.11
09

Study locations

78 sites
  • Research Site
    Los Angeles, California 90035, United States
  • Research Site
    Hartford, Connecticut 06102, United States
  • Research Site
    Washington, District of Columbia 20005, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Washington, District of Columbia 20037, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Tampa, Florida 33602, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Augusta, Georgia 30912, United States
  • Research Site
    Berkley, Michigan 48072, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Southfield, Michigan 48075, United States
  • Research Site
    Minneapolis, Minnesota 55415, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Camden, New Jersey 08103, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Falls Church, Virginia 22042, United States
  • Research Site
    Darlinghurst, New South Wales 2010, Australia
  • Research Site
    East Sydney, New South Wales 2010, Australia
  • Research Site
    Sydney, New South Wales 2010, Australia
  • Research Site
    Fortitude Valley, Queensland 4006, Australia
  • Research Site
    Melbourne, Victoria 3004, Australia
  • Research Site
    Prahran, Victoria 3181, Australia
  • Research Site
    Antwerp, 2000, Belgium
  • Research Site
    Brussels, 1000, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Sao Paulo, São Paulo 04121-000, Brazil
  • Research Site
    Rio de Janeiro, 21040-900, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Calgary, Alberta T2R 0X7, Canada
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Hamilton, Ontario L8S 1A4, Canada
  • Research Site
    Montreal, Quebec H4A 3T2, Canada
  • Research Site
    Quebec, G1V 4G2, Canada
  • Research Site
    Bordeaux, 33075, France
  • Research Site
    Lyon cedex 04, 69317, France
  • Research Site
    Montpellier cedex 5, 34295, France
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Paris Cedex 10, 75475, France
  • Research Site
    Paris Cedex 12, 75571, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Athens, 10676, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Athens, 16121, Greece
  • Research Site
    Thessaloniki, 54636, Greece
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Milano, 20157, Italy
  • Research Site
    Modena, 41100, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Roma, 00149, Italy
  • Research Site
    Warszawa, 01-201, Poland
  • Research Site
    Almada, 2801-951, Portugal
  • Research Site
    Aveiro, 3814-501, Portugal
  • Research Site
    Coimbra, 3000-075, Portugal
  • Research Site
    Porto, 4200-319, Portugal
  • Research Site
    Brasov, 500174, Romania
  • Research Site
    Bucharest, 021105, Romania
  • Research Site
    Constanta, 900708, Romania
  • Research Site
    Timisoara, 300310, Romania
  • Research Site
    Pretoria, Gauteng 0122, South Africa
  • Research Site
    Westdene, Gauteng 2092, South Africa
  • Research Site
    Bloemfontein, 9301, South Africa
  • Research Site
    Barcelona, Cataluña 08035, Spain
  • Research Site
    Barcelona, Cataluña 08036, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Geneva 14, 1211, Switzerland
  • Research Site
    Lausanne, 1011, Switzerland
  • Research Site
    Lugano, 6900, Switzerland
  • Research Site
    Zuerich, 8091, Switzerland
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    London, SW10 9NH, United Kingdom
  • Research Site
    London, W2 1NY, United Kingdom
10

References and documents

Publications

  • Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS; BEIJERINCK Investigators. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. J Am Coll Cardiol. 2020 May 26;75(20):2570-2584. doi: 10.1016/j.jacc.2020.03.025. Epub 2020 Mar 28. Erratum In: J Am Coll Cardiol. 2020 Aug 11;76(6):762-765. doi: 10.1016/j.jacc.2020.06.056. PubMed 32234462 ↗
  • Boccara F, Kumar P, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. Am Heart J. 2020 Feb;220:203-212. doi: 10.1016/j.ahj.2019.11.004. Epub 2019 Nov 12. PubMed 31841795 ↗
  • Boccara F, Caramelli B, Calmy A, Kumar P, Lopez JAG, Bray S, Cyrille M, Rosenson RS; investigators of the BEIJERINCK study. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. AIDS. 2022 Apr 1;36(5):675-682. doi: 10.1097/QAD.0000000000003175. PubMed 35025817 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jul 2019, 25 months.

Results were first posted in Jul 2020, 1 year after primary completion.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2016
First posted
Jul 14, 2016
StartActual
May 22, 2017
Primary completionActual
Jul 9, 2019
CompletionActual
Jan 27, 2020
Results first posted
Jul 21, 2020
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02833844
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 14, 2016
Start date
May 22, 2017
Primary completion
Jul 9, 2019
Completion
Jan 27, 2020
Results posted
Jul 21, 2020
Last update
Jul 22, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion